This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Q3 GDP +4.9%, Earnings Beats for UPS, Bristol Myers and Honeywell
by Mark Vickery
In the preliminary Q3 GDP print, consumer spending jumped to +4.0% while private domestic investment roared ahead +8.4%.
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
META Up +4% on +23% Revenue Growth; IBM and NOW Also Beat
by Mark Vickery
The social media leader posted a big beat on earnings -- $4.39 per share versus expectations of $3.62 and the year-ago number of $1.64 per share.
Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC
by Ahan Chakraborty
Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.
Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
by Zacks Equity Research
Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.
Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) reachead $57.17 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
by Zacks Equity Research
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
by Zacks Equity Research
Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
by Kinjel Shah
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
by Zacks Equity Research
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $56.61, indicating a -0.09% shift from the previous trading day.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
by Zacks Equity Research
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B
by Zacks Equity Research
Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $57.85 in the latest trading session, marking a -0.33% move from the prior day.
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
by Zacks Equity Research
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day.
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day.
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.